UnitedHealthcare · Injectafer · US health-plan appeal rights

Injectafer denied due to quantity / dose limits by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Injectafer denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

UnitedHealthcare's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: UHC Iron Sucrose & Ferumoxytol Policy / Injectafer PA — Step Therapy

The UnitedHealthcare angle on Injectafer

## Why UnitedHealthcare Applies Quantity Limits to Injectafer

UnitedHealthcare applies quantity limits to Injectafer (ferric carboxymaltose) as a cost-management tool. The plan's policy specifies a maximum number of doses, total grams of elemental iron, or infusion sessions within a defined period. A quantity-limit denial means UHC believes the requested amount exceeds what its policy considers appropriate for the stated indication, or that you have already received the allowed quantity within the coverage period. This type of denial is common when a condition is chronic and requires repeated iron repletion — for example, in patients with ongoing gastrointestinal blood loss or certain chronic conditions affecting iron absorption.

## Why This Denial Is Appealable

Quantity limits are set by policy, but clinical need is individual. If your prescriber has documented that your underlying condition causes recurrent iron deficiency requiring more frequent or larger-volume repletion than the standard limit anticipates, that clinical individualization is the basis of your appeal. The plan's standard quantity limit may simply not apply to patients with your specific medical circumstances.

## Your Federal Appeal Rights

Internal appeal (ACA §2719): File a written appeal explaining the clinical basis for exceeding the standard quantity limit.
External review: If the internal appeal is denied, an independent external reviewer — not affiliated with UHC — will evaluate whether the limit as applied to your case is clinically appropriate.
ERISA §503: For employer self-funded plans, demand the full claims file including the quantity-limit policy language used.
Expedited review: If continued anemia poses urgent risk, request expedited review.
Timeline: File external review within four months of the final internal denial.

## Documentation to Gather

1. Ongoing disease documentation: Records establishing the underlying cause of recurrent iron deficiency — specialist notes, procedural reports, lab trends over time. 2. Treatment history with dates: A log of prior Injectafer infusions, quantities received, lab values before and after each infusion, and how quickly iron stores were depleted. 3. Response-to-treatment records: Lab results showing the clinical response to prior infusions and the rate of re-depletion, demonstrating why the standard quantity is insufficient. 4. Prescriber medical-necessity letter: Your treating clinician should explain why your specific condition requires quantities beyond UHC's standard limit, referencing the applicable clinical guideline organization. 5. UHC's quantity-limit policy: Obtain and read the exact language of UHC's published quantity-limit criteria for Injectafer.

## Criteria-Mapping Structure

The quantity-limit appeal hinges on demonstrating that your clinical situation is materially different from the average case the limit was designed for. Your mapping table should include: (left column) each criterion in UHC's quantity-limit policy verbatim; (right column) the specific chart fact, lab value with date, or specialist note that justifies the exception. Supplement this with a graph or table of your iron-level trajectory over time if your clinician can provide it — visual evidence of rapid re-depletion is compelling to both internal reviewers and external review organizations.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other insurers on Injectafer

Other denial reasons for UnitedHealthcare Injectafer

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.